Supernus Pharmaceuticals Inc (SUPN)
35.82
-0.30
(-0.83%)
USD |
NASDAQ |
Nov 21, 16:00
35.81
-0.01
(-0.03%)
After-Hours: 20:00
Supernus Pharmaceuticals Enterprise Value: 1.575B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 1.575B |
| November 20, 2024 | 1.591B |
| November 19, 2024 | 1.559B |
| November 18, 2024 | 1.543B |
| November 15, 2024 | 1.561B |
| November 14, 2024 | 1.595B |
| November 13, 2024 | 1.682B |
| November 12, 2024 | 1.686B |
| November 11, 2024 | 1.618B |
| November 08, 2024 | 1.618B |
| November 07, 2024 | 1.607B |
| November 06, 2024 | 1.681B |
| November 05, 2024 | 1.515B |
| November 04, 2024 | 1.513B |
| November 01, 2024 | 1.473B |
| October 31, 2024 | 1.478B |
| October 30, 2024 | 1.522B |
| October 29, 2024 | 1.495B |
| October 28, 2024 | 1.483B |
| October 25, 2024 | 1.470B |
| October 24, 2024 | 1.463B |
| October 23, 2024 | 1.467B |
| October 22, 2024 | 1.458B |
| October 21, 2024 | 1.456B |
| October 18, 2024 | 1.504B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.465B |
| October 16, 2024 | 1.473B |
| October 15, 2024 | 1.448B |
| October 14, 2024 | 1.415B |
| October 11, 2024 | 1.419B |
| October 10, 2024 | 1.358B |
| October 09, 2024 | 1.385B |
| October 08, 2024 | 1.391B |
| October 07, 2024 | 1.367B |
| October 04, 2024 | 1.365B |
| October 03, 2024 | 1.369B |
| October 02, 2024 | 1.373B |
| October 01, 2024 | 1.364B |
| September 30, 2024 | 1.319B |
| September 27, 2024 | 1.347B |
| September 26, 2024 | 1.348B |
| September 25, 2024 | 1.303B |
| September 24, 2024 | 1.337B |
| September 23, 2024 | 1.384B |
| September 20, 2024 | 1.406B |
| September 19, 2024 | 1.423B |
| September 18, 2024 | 1.407B |
| September 17, 2024 | 1.401B |
| September 16, 2024 | 1.388B |
| September 13, 2024 | 1.367B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
757.21M
Minimum
Mar 18 2020
2.362B
Maximum
Apr 21 2023
1.489B
Average
1.465B
Median
Oct 17 2024
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals Inc | 74.00B |
| United Therapeutics Corp | 13.47B |
| Ligand Pharmaceuticals Inc | 1.983B |
| Tonix Pharmaceuticals Holding Corp | 17.92M |
| Agios Pharmaceuticals Inc | 2.163B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 38.50M |
| Revenue (Quarterly) | 175.69M |
| Total Expenses (Quarterly) | 135.86M |
| EPS Diluted (Quarterly) | 0.69 |
| Gross Profit Margin (Quarterly) | 89.99% |
| Profit Margin (Quarterly) | 21.91% |
| Earnings Yield | 2.99% |
| Operating Earnings Yield | 3.65% |
| Normalized Earnings Yield | 3.531 |